🇺🇸 FDA
Patent

US 12325750

Anti-Dectin-2 antibodies and methods of using

granted A61PA61P35/00

Quick answer

US patent 12325750 (Anti-Dectin-2 antibodies and methods of using) held by Bolt Biotherapeutics, Inc. expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Bolt Biotherapeutics, Inc.
Grant date
Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61P, A61P35/00